Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Jun 9;27(1):63.
doi: 10.1007/s11883-025-01304-z.

Recent Advances and Perspectives of Metabolomics-Based Investigations in Coronary Heart Disease

Jianping Hu #  1 , Jiaxin Zhou #  2 , Yong Liang  1 , Xiaotian Chen  1 , Hongdong Liu  1 , Bin Li  3 , Luqi Huang  4   5
Affiliations
Review

Recent Advances and Perspectives of Metabolomics-Based Investigations in Coronary Heart Disease

Jianping Hu et al. Curr Atheroscler Rep. .

Abstract

Purpose of review: Coronary heart disease (CHD) is a major global threat to human health. This review summarizes the latest progress of metabolomics in CHD research, and provides insights into the pathogenesis and identify dependable biomarkers of CHD.

Recent findings: This review has summarized 303 metabolic indicators related to CHD, with a focus on 53 biomarkers, and highlighted the top 10 biomarkers with significant clinical value. The biosynthesis of unsaturated fatty acids, amino acids, and aminoacyl-tRNA, as well as amino acid metabolism, are linked to CHD pathogenesis. Amino acids and lipids play essential roles in understanding the onset and progression of CHD. This review provides a new perspective on enhancing our understanding of CHD pathogenesis and developing effective treatment interventions.

Keywords: Biomarker; CHD; Metabolomics; Perspective; Review.

PubMed Disclaimer

Conflict of interest statement

Declarations. Human and Animal Rights and Informed Consent: No animal or human subjects were used by the authors in this study. Competing interests: The authors declare no competing interests.

References

    1. Kordalewska M, Markuszewski MJ. Metabolomics in cardiovascular diseases. J Pharm Biomed Anal. 2015;113:121–36. https://doi.org/10.1016/j.jpba.2015.04.021 . - DOI - PubMed
    1. Nock S, Karim E, Unsworth AJ. Pim Kinases: Important Regulators of Cardiovascular Disease. Int J Mol Sci. 2023;24(14):11582. https://doi.org/10.3390/ijms241411582 . - DOI - PubMed - PMC
    1. Meikle PJ, Wong G, Barlow CK, Kingwell BA. Lipidomics: potential role in risk prediction and therapeutic monitoring for diabetes and cardiovascular disease. Pharmacol Ther. 2014;143(1):12–23. https://doi.org/10.1016/j.pharmthera.2014.02.001 . - DOI - PubMed
    1. Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, et al. Executive Summary: Heart Disease and Stroke Statistics–2016 Update: A Report From the American Heart Association. Circulation. 2016;133(4):447–54. https://doi.org/10.1161/CIR.0000000000000366 . - DOI - PubMed
    1. Shah SH, Kraus WE, Newgard CB. Metabolomic profiling for the identification of novel biomarkers and mechanisms related to common cardiovascular diseases: form and function. Circulation. 2012;126(9):1110–20. https://doi.org/10.1161/CIRCULATIONAHA.111.060368 . - DOI - PubMed - PMC

LinkOut - more resources